Exposure to CM obtained from different cancer cells induced morphological changes and expression levels of MuRF‐1 and Atrogin‐1 which are representative muscle atrophy markers, but BSN suppressed expression of these proteins in CM‐treated C2C12 cells. Here, FBXO32 is linked to cancer.